6 Papers
29 Citations
A. Testori is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Alpha (ethology) & T cell. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
A.M. Di Giacomo,P.A. Ascierto,Paola Queirolo,Lorenzo Pilla,Ruggero Ridolfi,Mario Santinami,A. Testori,Ester Simeone,Massimo Guidoboni,Andrea Maurichi,L. Orgiano,Giuseppe Spadola,M. Del Vecchio,Riccardo Danielli,Luana Calabrò,Diego Annesi,Diana Giannarelli,Cristina Maccalli,Ester Fonsatti,Giorgio Parmiani,Michele Maio +20 more
TL;DR: Long-term analysis of the NIBIT-M1 trial continues to demonstrate efficacy of ipilimumab combined with fotemustine in MM patients, and fotamustine does not seem to impair the immunologic activity of ipILimumab.
135
Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized phase III trial in stage IV melanoma
Jon M. Richards,A. Testori,Eric D. Whitman,G. B. Mann,Jose Lutzky,Luis H. Camacho,Giorgio Parmiani,Axel Hoos,Gupta Rm,Pramod K. Srivastava +9 more
TL;DR: If 10 doses of vaccine can be administered, vitespen also appears to confer survival benefit over PC for M1a melanoma pts, and a phase 3 trial evaluating vites pen in M1 a and M1b pts is planned.
18
A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results
Roberto Camerini,Andrzej Mackiewicz,A. Testori,Uwe Trefzer,Jacek Jassem,Virginia Ferraresi,Michele Maio,Claus Garbe,A. Lange,P. Carminati +9 more
TL;DR: Phase II, randomized, stratified, open-study testing different doses of Ta1 in association with DTIC and IFNa, as first-line therapy in stage IV melanoma patients (AJCC 2001) without brain metastases, reports a dose-response effect and primary endpoint is tumor response and secondary overall survival.
10
Improved survival for stage III/IV melanoma from an unknown primary site (MUP): An Italian multicentric study.
Michele Guida,A. Muggiano,D. Albano,Ruggero Ridolfi,A. Testori,Vanna Chiarion-Sileni,Mario Roberto Sertoli,Antonella Romanini,Giorgio Parmiani,Giuseppe Colucci +9 more
TL;DR: A large number of the MUPs diagnosed in this study were new to the literature and had not been seen before in any other type of melanomas.
1
V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings
Filiberto Belli,A. Testori,Licia Rivoltini,Michele Maio,Giovanna Andreola,Mario Roberto Sertoli,Gianfrancesco Gallino,Adriano Piris,Alessandro Cattelan,Ivano Lazzari,Matteo Carrabba,Giorgio Scita,Cristina Santantonio,Lorenzo Pilla,Gabrina Tragni,Claudia Lombardo,Flavio Arienti,Alfonso Marchianò,Paola Queirolo,Francesco Bertolini,Agata Cova,Elda Lamaj,Lucio Ascani,Roberto Camerini,Marco Corsi,Natale Cascinelli,Jonathan J. Lewis,Pramod K. Srivastava,Giorgio Parmiani +28 more
- 01 Jan 2002
TL;DR: This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients, demonstrating that vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity.